[The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
Optimal duration of immunotherapy treatment by BCG for the prevention of recurrences of superficial bladder cancer is still unknown. We have studied the evolution and duration of the cellular immunity response at the peripheral level after BCG intravesical instillations. Our results show that immunity activation after BCG is of short duration and don't take more than 6 months. Our results support, strengthen and partially allow to explain the utility of maintenance treatment by BCG following 6-weekly instillations.
Shekarsarai
H
H
Département dUrologie, Hôpital Universitaire Erasme, Bruxelles, Belgique.
Zlotta
A R
AR
Drowart
A
A
Van Vooren
J P
JP
De Cock
M
M
Pirson
M
M
Palfliet
K
K
Jurion
F
F
Vanonckelen
A
A
Simon
J
J
Schulman
C C
CC
Huygen
K
K
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000096:biosynthesis; D004724:Endoscopy; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000601:surgery / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D016207:Cytokines
La nécessité d'un traitement prolongé par BCG dans les cancers superficiels de la vessie est suggérée par l'évolution de la réponse immunitaire périphérique induite par le BCG.